Christine Lee, MD
Gynecologic Oncology · Shenandoah, TXNPI 1043295728
Payments from drug & device makers
Across 934 payments — averaging $6774.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$2.5M
- Merck$2.1M
- GSK$1.1M
- Tesaro, Inc.$287K
- Genentech, Inc.$119K
- Genmab U.S., Inc.$75K
- plus $67K from 17 others
What the payments were for
- Travel & lodging$83947%
- Food & beverage$85648%
- Education$1006%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 326 | $2,506,748 |
| Merck | 395 | $2,132,867 |
| GSK | 107 | $1,140,004 |
| Tesaro, Inc. | 22 | $287,039 |
| Genentech, Inc. | 7 | $118,578 |
| Genmab U.S., Inc. | 3 | $75,270 |
| Karyopharm Therapeutics Inc. | 2 | $32,350 |
| AstraZeneca | 2 | $15,717 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,243 |
| Pfizer | 7 | $4,844 |
| Organon | 2 | $3,620 |
| Seagen Inc. | 4 | $2,627 |
| Incyte Corporation | 40 | $900 |
| AbbVie | 3 | $147 |
| Merz North America, Inc. | 1 | $121 |
| Tempus AI, Inc | 2 | $117 |
| Coopersurgical, Inc. | 2 | $51 |
| Wound Management Technologies, Inc | 1 | $25 |
| Sirtex Medical Inc | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Immunogen, Inc. | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,327,373 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 91 | $714 |
| Anastrozole | 31 | $472 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 33 | $240 |
| Ondansetron Hcl | 15 | $103 |
| Gabapentin | 12 | $70 |
| Tramadol Hcl | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Shenandoah
- Pamela SolimanHouston$30.7M
- Noelle ClovenFort Worth$7.3M
- Antonio Santillan-GomezSan Antonio$4.5M
- Jayanthi LeaDallas$3.9M
- Helen EshedAustin$3.5M
- Robert ColemanHouston$3.4M
- Michael TenerielloAustin$2.9M
- Heather PulaskiTyler$2.5M
- David MillerDallas$2M
- Anna PriebeTyler$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.